PMC:7228307 / 41185-41441 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"689","span":{"begin":94,"end":101},"obj":"Gene"},{"id":"691","span":{"begin":144,"end":148},"obj":"Gene"},{"id":"703","span":{"begin":26,"end":32},"obj":"Disease"}],"attributes":[{"id":"A689","pred":"tao:has_database_id","subj":"689","obj":"Gene:2213"},{"id":"A691","pred":"tao:has_database_id","subj":"691","obj":"Gene:2213"},{"id":"A703","pred":"tao:has_database_id","subj":"703","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T355","span":{"begin":33,"end":37},"obj":"Body_part"},{"id":"T356","span":{"begin":215,"end":219},"obj":"Body_part"},{"id":"T357","span":{"begin":251,"end":255},"obj":"Body_part"}],"attributes":[{"id":"A355","pred":"fma_id","subj":"T355","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A356","pred":"fma_id","subj":"T356","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A357","pred":"fma_id","subj":"T357","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T67","span":{"begin":26,"end":32},"obj":"Disease"}],"attributes":[{"id":"A67","pred":"mondo_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T738","span":{"begin":33,"end":37},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T739","span":{"begin":94,"end":96},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T740","span":{"begin":116,"end":125},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T741","span":{"begin":133,"end":143},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T742","span":{"begin":144,"end":146},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T743","span":{"begin":215,"end":219},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T744","span":{"begin":251,"end":255},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T216","span":{"begin":206,"end":214},"obj":"Chemical"}],"attributes":[{"id":"A216","pred":"chebi_id","subj":"T216","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"}],"text":"Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T208","span":{"begin":33,"end":37},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T209","span":{"begin":215,"end":219},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T210","span":{"begin":251,"end":255},"obj":"http://purl.obolibrary.org/obo/CL_0000000"}],"text":"Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"689","span":{"begin":94,"end":101},"obj":"Gene"},{"id":"691","span":{"begin":144,"end":148},"obj":"Gene"},{"id":"703","span":{"begin":26,"end":32},"obj":"Disease"}],"attributes":[{"id":"A689","pred":"pubann:denotes","subj":"689","obj":"Gene:2213"},{"id":"A691","pred":"pubann:denotes","subj":"691","obj":"Gene:2213"},{"id":"A703","pred":"pubann:denotes","subj":"703","obj":"MESH:D009369"}],"text":"Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T232","span":{"begin":0,"end":256},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T354","span":{"begin":33,"end":37},"obj":"Body_part"},{"id":"T355","span":{"begin":215,"end":219},"obj":"Body_part"},{"id":"T356","span":{"begin":251,"end":255},"obj":"Body_part"}],"attributes":[{"id":"A354","pred":"fma_id","subj":"T354","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A355","pred":"fma_id","subj":"T355","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A356","pred":"fma_id","subj":"T356","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell."}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T105","span":{"begin":116,"end":125},"obj":"http://purl.obolibrary.org/obo/GO_0023052"}],"text":"Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T24","span":{"begin":26,"end":32},"obj":"Disease"}],"attributes":[{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell."}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T14","span":{"begin":26,"end":32},"obj":"Phenotype"}],"attributes":[{"id":"A14","pred":"hp_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell."}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T105","span":{"begin":116,"end":125},"obj":"http://purl.obolibrary.org/obo/GO_0023052"}],"text":"Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T105","span":{"begin":116,"end":125},"obj":"http://purl.obolibrary.org/obo/GO_0023052"}],"text":"Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell."}

{"project":"LitCovid-sentences","denotations":[{"id":"T232","span":{"begin":0,"end":256},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T14","span":{"begin":26,"end":32},"obj":"Phenotype"}],"attributes":[{"id":"A14","pred":"hp_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell."}